Several studies have reported that TGF-β pathway transduction disorder is very common in ccRCC and that inhibition of TGF-β pathway is considered to be a promising forms of treatment for ccRCC (20, 21). The gene discussed is TGFB1; the disease is nonpapillary renal cell carcinoma.